US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Zenas BioPharma Inc.

31.12

+0.02000.06%

Post-market: 30.92-0.2000-0.64%16:49 EDT

Volume:421.69K

Turnover:13.27M

Market Cap:2.03B

PE:-3.44

High:32.32

Open:31.48

Low:31.12

Close:31.10

52wk High:44.60

52wk Low:13.50

Shares:65.18M

Float Shares:47.02M

Volume Ratio:0.86

T/O Rate:0.90%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-9.0522

EPS(LYR):-8.4448

ROE:-199.04%

ROA:-34.42%

PB:8.21

PE(LYR):-3.69

Loading ...

Overview Company News Filings

BUZZ-Zenas BioPharma drops on convertible, equity offerings

Zenas Biopharma announces underwritten public offering of convertible senior notes due 2032; terms are set at pricing

Zenas Biopharma Inc - Proceeds to Support Obexelimab U.S. Launch, Pipeline Advancement, and General Corporate Purposes

THOMSON REUTERS

Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock

Zenas BioPharma Advances Phase 3 Orelabrutinib Trial in Progressive Multiple Sclerosis

Wedbush Sticks to Its Buy Rating for Zenas BioPharma, Inc. (ZBIO)

Zenas BioPharma Is Maintained at Equal-Weight by Morgan Stanley

Zenas BioPharma Price Target Maintained With a $44.00/Share by HC Wainwright & Co.

Zenas BioPharma: De‑Risked Autoimmune Late‑Stage Assets and Strong Balance Sheet Underpin Buy Rating and $44 Target

Zenas BioPharma price target lowered to $41 from $43 at Citi

IPO-Related Securities Class Action Poses Ongoing Financial and Operational Risks for Zenas BioPharma

Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma Inc. Announces Annual Stockholders Meeting

Earnings Flash (ZBIO) Zenas BioPharma Posts Q4 Net Loss $4.54 a Share

MT Newswires Live

Zenas BioPharma Q4 EPS $(4.54) Down From $(1.26) YoY

Benzinga Earnings

Zenas BioPharma Q4 net loss rose 357% to USD 240.44 million

Press Release: Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/ZBIO/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"ZBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZBIO\",,,,,undefined,":{"symbol":"ZBIO","market":"US","secType":"STK","nameCN":"Zenas BioPharma Inc.","latestPrice":31.12,"timestamp":1789156800000,"preClose":31.1,"halted":0,"volume":421685,"hourTrading":{"tag":"盘后","latestPrice":30.92,"preClose":31.12,"latestTime":"16:49 EDT","volume":12096,"amount":376423.867008,"timestamp":1789159794776,"change":-0.2,"changeRate":-0.006427,"amplitude":0.011568},"delay":0,"changeRate":0.0006430868167202435,"floatShares":47024692,"shares":65176700,"eps":-9.052203,"marketStatus":"Post-Mkt","change":0.02,"latestTime":"09-11 16:54:29 EDT","open":31.48,"high":32.315,"low":31.12,"amount":13274881.63034,"amplitude":0.038424,"askPrice":31.23,"askSize":1,"bidPrice":25.61,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-9.052203,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789171200000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":31.1,"sharesOutstanding":249967,"nav":10.0592,"aum":2514468.0464,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":31.21,"preClose":31.1,"latestTime":"08:53 EDT","volume":41,"amount":1279.3800310000001,"timestamp":1789131189009,"change":0.11,"changeRate":0.003537,"amplitude":0.003537},"postHourTrading":{"tag":"盘后","latestPrice":30.92,"preClose":31.12,"latestTime":"16:49 EDT","volume":12096,"amount":376423.867008,"timestamp":1789159794776,"change":-0.2,"changeRate":-0.006427,"amplitude":0.011568},"volumeRatio":0.863638,"impliedVol":0.7397,"impliedVolPercentile":0.2629},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZBIO\",,,,,undefined,":{"symbol":"ZBIO","floatShares":47024692,"roa":"-34.42%","roe":"-199.04%","lyrEps":-8.444814,"volumeRatio":0.863638,"shares":65176700,"dividePrice":0,"high":32.315,"amplitude":0.038424,"preClose":31.1,"low":31.12,"week52Low":13.5,"pbRate":"8.21","psRate":"2028.30","week52High":44.6,"institutionHeld":0,"latestPrice":31.12,"committee":0.980198,"eps":-9.052203,"divideRate":0,"volume":421685,"delay":0,"ttmEps":-9.052203,"open":31.48,"prevYearClose":36.31,"prevWeekClose":32.88,"prevMonthClose":32.32,"prevQuarterClose":25.38,"fiveDayClose":32.92,"twentyDayClose":29.2,"sixtyDayClose":18.19},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ZBIO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"ZBIO","fiscalQuarterEnding":"2026/06","expectedEps":-0.89,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"pre","actualEps":-1.77},{"market":"US","date":"2026-05-13","symbol":"ZBIO","fiscalQuarterEnding":"2026/03","expectedEps":-1.37,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778644800000,"reportTimeType":"pre","actualEps":-1.46},{"market":"US","date":"2026-03-16","symbol":"ZBIO","fiscalQuarterEnding":"2025/12","expectedEps":-1.22,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1773633600000,"reportTimeType":"pre","actualEps":-4.54},{"market":"US","date":"2025-11-12","symbol":"ZBIO","fiscalQuarterEnding":"2025/09","expectedEps":-0.87,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-1.22},{"market":"US","date":"2025-08-12","symbol":"ZBIO","fiscalQuarterEnding":"2025/06","expectedEps":-1.02,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-1.25}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ZBIO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ZBIO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.625,"buy":0.25,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.625,"analysts":8,"updateTime":1767758400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ZBIO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ZBIO","date":"2026-09-10","current":-3.437837,"percent":0.412475,"low":-19.592941,"twenty":-7.32234,"median":-3.934344,"eighty":-2.629215,"high":-1.802568,"avg":-5.286836,"sd":3.685737,"marketCap":2104556385},"quantilePoints":[{"date":"2024-09-13","current":-8.364044,"twenty":-11.189626,"median":-10.130033,"eighty":-9.07044,"marketCap":457989962},{"date":"2024-09-20","current":-12.731934,"twenty":-12.968841,"median":-12.731934,"eighty":-9.523082,"marketCap":697162515},{"date":"2024-09-27","current":-12.564791,"twenty":-13.484804,"median":-12.909978,"eighty":-12.029776,"marketCap":688010267},{"date":"2024-10-04","current":-14.275075,"twenty":-13.747873,"median":-12.811872,"eighty":-12.31335,"marketCap":781660299},{"date":"2024-10-11","current":-13.008553,"twenty":-13.941177,"median":-13.027627,"eighty":-12.397648,"marketCap":712309358},{"date":"2024-10-18","current":-16.373229,"twenty":-14.273549,"median":-13.29848,"eighty":-12.477586,"marketCap":896548905},{"date":"2024-10-25","current":-17.845752,"twenty":-15.022781,"median":-13.503182,"eighty":-12.59822,"marketCap":977179818},{"date":"2024-10-31","current":-16.022265,"twenty":-16.022265,"median":-13.891034,"eighty":-12.731934,"marketCap":877331175},{"date":"2024-11-08","current":-15.961228,"twenty":-15.961228,"median":-14.267446,"eighty":-12.811872,"marketCap":873988961},{"date":"2024-11-15","current":-6.06727,"twenty":-16.022265,"median":-14.202594,"eighty":-12.564791,"marketCap":782495852},{"date":"2024-11-22","current":-3.382919,"twenty":-15.961228,"median":-13.807463,"eighty":-11.896022,"marketCap":436298426},{"date":"2024-11-29","current":-3.729636,"twenty":-15.955124,"median":-13.496851,"eighty":-6.578437,"marketCap":481014835},{"date":"2024-12-06","current":-3.402361,"twenty":-15.898664,"median":-13.178717,"eighty":-4.851473,"marketCap":438805888},{"date":"2024-12-13","current":-2.997318,"twenty":-15.744546,"median":-13.008553,"eighty":-3.729636,"marketCap":386567092},{"date":"2024-12-20","current":-3.162575,"twenty":-15.636205,"median":-12.771903,"eighty":-3.606503,"marketCap":407880521},{"date":"2024-12-27","current":-3.256545,"twenty":-15.585849,"median":-12.510288,"eighty":-3.394584,"marketCap":419999921},{"date":"2025-01-03","current":-2.91955,"twenty":-15.427152,"median":-12.339512,"eighty":-3.24488,"marketCap":376537243},{"date":"2025-01-10","current":-3.007039,"twenty":-15.189107,"median":-10.412935,"eighty":-3.188498,"marketCap":387820823},{"date":"2025-01-17","current":-2.520987,"twenty":-15.022781,"median":-6.676265,"eighty":-3.159983,"marketCap":325134267},{"date":"2025-01-24","current":-2.715408,"twenty":-14.870188,"median":-6.06727,"eighty":-3.071846,"marketCap":350208890},{"date":"2025-01-31","current":-2.469142,"twenty":-14.351372,"median":-4.794107,"eighty":-2.968155,"marketCap":318447701},{"date":"2025-02-07","current":-2.54367,"twenty":-14.313224,"median":-3.888412,"eighty":-2.841781,"marketCap":328059640},{"date":"2025-02-14","current":-2.313605,"twenty":-14.275075,"median":-3.716674,"eighty":-2.653842,"marketCap":298388004},{"date":"2025-02-21","current":-2.530708,"twenty":-14.268972,"median":-3.643766,"eighty":-2.622086,"marketCap":326387998},{"date":"2025-02-28","current":-2.141867,"twenty":-14.163683,"median":-3.476889,"eighty":-2.54367,"marketCap":276238754},{"date":"2025-03-07","current":-2.35573,"twenty":-14.007233,"median":-3.332693,"eighty":-2.517747,"marketCap":303820838},{"date":"2025-03-14","current":-2.324434,"twenty":-13.840892,"median":-3.246824,"eighty":-2.465902,"marketCap":364908203},{"date":"2025-03-21","current":-2.26852,"twenty":-13.569102,"median":-3.188498,"eighty":-2.360915,"marketCap":356130342},{"date":"2025-03-28","current":-2.138053,"twenty":-13.499383,"median":-3.165816,"eighty":-2.351842,"marketCap":335648668},{"date":"2025-04-04","current":-2.076814,"twenty":-13.408148,"median":-3.159335,"eighty":-2.284767,"marketCap":326034820},{"date":"2025-04-11","current":-1.80523,"twenty":-13.315978,"median":-3.071846,"eighty":-2.26652,"marketCap":283399498},{"date":"2025-04-17","current":-2.21793,"twenty":-13.154764,"median":-2.997318,"eighty":-2.257224,"marketCap":348188468},{"date":"2025-04-25","current":-2.657256,"twenty":-13.051602,"median":-2.943853,"eighty":-2.261324,"marketCap":417157373},{"date":"2025-05-02","current":-3.077944,"twenty":-13.023813,"median":-2.968155,"eighty":-2.26639,"marketCap":483200324},{"date":"2025-05-09","current":-2.4756,"twenty":-13.008271,"median":-2.943853,"eighty":-2.269325,"marketCap":388639550},{"date":"2025-05-16","current":-2.503456,"twenty":-12.890356,"median":-2.890387,"eighty":-2.270833,"marketCap":407464932},{"date":"2025-05-23","current":-2.942974,"twenty":-12.763909,"median":-2.866084,"eighty":-2.272453,"marketCap":479001383},{"date":"2025-05-30","current":-2.570283,"twenty":-12.665077,"median":-2.835832,"eighty":-2.278934,"marketCap":418341820},{"date":"2025-06-06","current":-2.470042,"twenty":-12.521189,"median":-2.721889,"eighty":-2.297829,"marketCap":402026489},{"date":"2025-06-13","current":-2.90956,"twenty":-12.426717,"median":-2.835832,"eighty":-2.31327,"marketCap":473562940},{"date":"2025-06-20","current":-2.392933,"twenty":-12.365673,"median":-2.76689,"eighty":-2.315238,"marketCap":389476234},{"date":"2025-06-27","current":-2.608837,"twenty":-12.215932,"median":-2.714219,"eighty":-2.322158,"marketCap":424616947},{"date":"2025-07-03","current":-2.577994,"twenty":-11.896022,"median":-2.691086,"eighty":-2.323707,"marketCap":419596845},{"date":"2025-07-11","current":-3.102331,"twenty":-8.929847,"median":-2.679496,"eighty":-2.324434,"marketCap":504938576},{"date":"2025-07-18","current":-3.387633,"twenty":-8.364044,"median":-2.699206,"eighty":-2.336288,"marketCap":551374518},{"date":"2025-07-25","current":-4.194702,"twenty":-6.676265,"median":-2.718649,"eighty":-2.349239,"marketCap":682733850},{"date":"2025-08-01","current":-4.037914,"twenty":-6.187126,"median":-2.829882,"eighty":-2.35573,"marketCap":657214999},{"date":"2025-08-08","current":-3.804019,"twenty":-6.06727,"median":-2.865865,"eighty":-2.35573,"marketCap":619145893},{"date":"2025-08-15","current":-3.987237,"twenty":-5.542498,"median":-2.90956,"eighty":-2.36209,"marketCap":705768845},{"date":"2025-08-22","current":-4.02768,"twenty":-4.889717,"median":-2.928692,"eighty":-2.362211,"marketCap":712927599},{"date":"2025-08-29","current":-3.868286,"twenty":-4.698498,"median":-2.950685,"eighty":-2.372371,"marketCap":684713689},{"date":"2025-09-05","current":-4.039575,"twenty":-4.396216,"median":-2.982091,"eighty":-2.374493,"marketCap":715033114},{"date":"2025-09-12","current":-4.798483,"twenty":-4.881439,"median":-2.99503,"eighty":-2.389351,"marketCap":849365013},{"date":"2025-09-19","current":-4.629572,"twenty":-4.881439,"median":-3.063777,"eighty":-2.399463,"marketCap":819466690},{"date":"2025-09-26","current":-4.429735,"twenty":-4.835595,"median":-3.074895,"eighty":-2.402603,"marketCap":784094028},{"date":"2025-10-03","current":-4.984046,"twenty":-4.911724,"median":-3.083269,"eighty":-2.409912,"marketCap":882211057},{"date":"2025-10-10","current":-6.604159,"twenty":-5.180553,"median":-3.135974,"eighty":-2.413574,"marketCap":1168982288},{"date":"2025-10-17","current":-5.759607,"twenty":-5.320916,"median":-3.162575,"eighty":-2.420654,"marketCap":1019490677},{"date":"2025-10-24","current":-5.949928,"twenty":-5.76722,"median":-3.174048,"eighty":-2.42495,"marketCap":1053178928},{"date":"2025-10-31","current":-9.035303,"twenty":-6.083769,"median":-3.188498,"eighty":-2.432369,"marketCap":1599311910},{"date":"2025-11-07","current":-9.81546,"twenty":-6.198298,"median":-3.245204,"eighty":-2.444339,"marketCap":1737405107},{"date":"2025-11-14","current":-10.08009,"twenty":-6.457611,"median":-3.282468,"eighty":-2.446909,"marketCap":1914199059},{"date":"2025-11-21","current":-9.848299,"twenty":-7.258864,"median":-3.371139,"eighty":-2.451734,"marketCap":1870182143},{"date":"2025-11-28","current":-10.976161,"twenty":-8.972029,"median":-3.394997,"eighty":-2.453948,"marketCap":2084362015},{"date":"2025-12-05","current":-10.772637,"twenty":-9.459248,"median":-3.515773,"eighty":-2.459247,"marketCap":2045713016},{"date":"2025-12-12","current":-11.366249,"twenty":-9.83041,"median":-3.643766,"eighty":-2.466418,"marketCap":2158439264},{"date":"2025-12-19","current":-9.913314,"twenty":-9.980024,"median":-3.678075,"eighty":-2.469682,"marketCap":1882528351},{"date":"2025-12-26","current":-12.202958,"twenty":-10.134363,"median":-3.729636,"eighty":-2.472265,"marketCap":2317329596},{"date":"2026-01-02","current":-10.263827,"twenty":-10.232168,"median":-3.760324,"eighty":-2.476253,"marketCap":1949090517},{"date":"2026-01-09","current":-4.638651,"twenty":-10.207521,"median":-3.79333,"eighty":-2.479511,"marketCap":880875114},{"date":"2026-01-16","current":-5.633657,"twenty":-10.159019,"median":-3.831007,"eighty":-2.483289,"marketCap":1069825778},{"date":"2026-01-23","current":-5.766513,"twenty":-10.142278,"median":-3.88256,"eighty":-2.488034,"marketCap":1095054986},{"date":"2026-01-30","current":-5.902195,"twenty":-10.122491,"median":-3.950232,"eighty":-2.490604,"marketCap":1120820986},{"date":"2026-02-06","current":-5.938943,"twenty":-10.119664,"median":-3.975342,"eighty":-2.498305,"marketCap":1127799277},{"date":"2026-02-13","current":-7.380571,"twenty":-10.08009,"median":-4.008147,"eighty":-2.503456,"marketCap":1401563024},{"date":"2026-02-20","current":-7.637803,"twenty":-9.946669,"median":-4.026371,"eighty":-2.50452,"marketCap":1450411065},{"date":"2026-02-27","current":-7.451239,"twenty":-9.897484,"median":-4.035344,"eighty":-2.514003,"marketCap":1414982815},{"date":"2026-03-06","current":-7.140299,"twenty":-9.857345,"median":-4.041954,"eighty":-2.520051,"marketCap":1355935733},{"date":"2026-03-13","current":-6.925469,"twenty":-9.824447,"median":-4.068124,"eighty":-2.528764,"marketCap":1315139567},{"date":"2026-03-20","current":-3.549457,"twenty":-9.816065,"median":-4.041954,"eighty":-2.535893,"marketCap":1340761298},{"date":"2026-03-27","current":-3.365681,"twenty":-9.764845,"median":-4.035344,"eighty":-2.542374,"marketCap":1271342335},{"date":"2026-04-02","current":-3.206266,"twenty":-9.752191,"median":-4.02768,"eighty":-2.54367,"marketCap":1211125146},{"date":"2026-04-10","current":-3.351146,"twenty":-9.585134,"median":-4.008147,"eighty":-2.555011,"marketCap":1265851823},{"date":"2026-04-17","current":-3.426736,"twenty":-9.459248,"median":-3.975342,"eighty":-2.562572,"marketCap":1294404871},{"date":"2026-04-24","current":-2.91178,"twenty":-9.318941,"median":-3.950232,"eighty":-2.56484,"marketCap":1099887227},{"date":"2026-05-01","current":-3.042488,"twenty":-9.220114,"median":-3.88256,"eighty":-2.568711,"marketCap":1149260207},{"date":"2026-05-08","current":-3.034614,"twenty":-9.118797,"median":-3.818719,"eighty":-2.573367,"marketCap":1146285931},{"date":"2026-05-15","current":-2.806581,"twenty":-9.04377,"median":-3.782641,"eighty":-2.576966,"marketCap":1193220825},{"date":"2026-05-22","current":-2.946168,"twenty":-8.972029,"median":-3.74498,"eighty":-2.576966,"marketCap":1252566199},{"date":"2026-05-29","current":-2.756092,"twenty":-8.703526,"median":-3.716674,"eighty":-2.577994,"marketCap":1171755477},{"date":"2026-06-05","current":-2.729363,"twenty":-8.073548,"median":-3.672934,"eighty":-2.577994,"marketCap":1160391469},{"date":"2026-06-12","current":-2.637295,"twenty":-7.609535,"median":-3.597675,"eighty":-2.580331,"marketCap":1121248775},{"date":"2026-06-18","current":-2.759062,"twenty":-7.566764,"median":-3.544789,"eighty":-2.584211,"marketCap":1173018144},{"date":"2026-06-26","current":-3.663405,"twenty":-7.560564,"median":-3.528998,"eighty":-2.58741,"marketCap":1557500410},{"date":"2026-07-02","current":-4.157898,"twenty":-7.541694,"median":-3.549457,"eighty":-2.594231,"marketCap":1767734556},{"date":"2026-07-10","current":-4.370248,"twenty":-7.462546,"median":-3.643766,"eighty":-2.595516,"marketCap":1858015285},{"date":"2026-07-17","current":-4.193537,"twenty":-7.451239,"median":-3.672934,"eighty":-2.596017,"marketCap":1782886566},{"date":"2026-07-24","current":-4.601902,"twenty":-7.448412,"median":-3.716674,"eighty":-2.598756,"marketCap":1956503353},{"date":"2026-07-31","current":-4.791978,"twenty":-7.400923,"median":-3.74498,"eighty":-2.598756,"marketCap":2037314075},{"date":"2026-08-07","current":-4.777128,"twenty":-7.389051,"median":-3.770746,"eighty":-2.606821,"marketCap":2031000738},{"date":"2026-08-14","current":-3.929032,"twenty":-7.382267,"median":-3.79905,"eighty":-2.610296,"marketCap":1903160311},{"date":"2026-08-21","current":-4.254657,"twenty":-7.371525,"median":-3.831007,"eighty":-2.614149,"marketCap":2060887981},{"date":"2026-08-28","current":-4.389213,"twenty":-7.360218,"median":-3.875423,"eighty":-2.618299,"marketCap":2126064704},{"date":"2026-09-04","current":-4.42958,"twenty":-7.333082,"median":-3.927729,"eighty":-2.626159,"marketCap":2145617721},{"date":"2026-09-10","current":-4.34481,"twenty":-7.32234,"median":-3.934344,"eighty":-2.629215,"marketCap":2104556385}],"updateTime":1789160069195},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ZBIO\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622689145","title":"BUZZ-Zenas BioPharma drops on convertible, equity offerings","url":"https://stock-news.laohu8.com/highlight/detail?id=2622689145","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622689145?lang=en_us&edition=fundamental","pubTime":"2026-03-27 05:15","pubTimestamp":1774559710,"startTime":"0","endTime":"0","summary":"BUZZ-Zenas BioPharma drops on convertible, equity offerings** Zenas BioPharma ZBIO.O shares down 9.8% post-market to $20 after capital raise news ** Autoimmune disease specialist commences public offerings of 6-yr convertible bonds and common stock without disclosing deal sizes** Says intends to use net proceeds from both offerings, which are not conditioned upon each other, to support planned U.S. commercial launch of obexelimab, if approved, and advance its development pipeline** Jefferies, Evercore, Citigroup and Guggenheim Secs joint bookrunners** On Jan 5, ZBIO shares plunged 52% after obexelimab cut the risk of flare-ups in patients with immunoglobulin G4-related disease, but showed weaker-than-expected efficacy in a late-stage study** ZBIO stock closed down 0.1% at $22.16 on Thurs. Stock off 39% YTD after surging more than four-fold in 2025** Waltham, Massachusetts-based co has ~57.4 mln shares outstanding for ~$1.3 bln market cap** Avg rating of 8 analysts is \"strong buy\"; medi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nL6N40E1B8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2360032135.SGD","LU0314106906.USD","LU0072461881.USD","LU0648001328.SGD","LU0980610538.SGD","BK4127","LU1244550577.SGD","LU2417539215.USD","BK4559","LU0310800965.SGD","LU1162221912.USD","LU1201861249.SGD","LU0098860793.USD","LU2456880835.USD","LU0106831901.USD","LU0170899867.USD","BK4504","BK4207","BK4588","LU1267930227.SGD","LU2462157665.USD","LU0052756011.USD","BK4566","LU0320765646.SGD","LU1506573853.SGD","LU1668664300.SGD","IE00BSNM7G36.USD","LU2125154778.USD","LU2125154935.USD","LU0130102774.USD","LU1244550494.USD","LU1791807156.HKD","LU2236285917.USD","LU1244550221.USD","LU0130517989.USD","BK4139","LU0162691827.USD","LU0477156953.USD","LU1366192091.USD","BK4534","EVR","ZBIO","BK4585","LU0128525689.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622896665","title":"Zenas Biopharma announces underwritten public offering of convertible senior notes due 2032; terms are set at pricing","url":"https://stock-news.laohu8.com/highlight/detail?id=2622896665","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622896665?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:04","pubTimestamp":1774555482,"startTime":"0","endTime":"0","summary":"The notes are general, unsecured, senior obligations with interest payable semi-annually.Underwriters have a 30-day option to buy up to an additional 15% of the notes to cover over-allotments.The interest rate, conversion rate and offering price will be set at pricing.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief on March 26, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDL5lSgF0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622511896","title":"Zenas Biopharma Inc - Proceeds to Support Obexelimab U.S. Launch, Pipeline Advancement, and General Corporate Purposes","url":"https://stock-news.laohu8.com/highlight/detail?id=2622511896","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622511896?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:01","pubTimestamp":1774555260,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nTUA8TLJWF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622966968","title":"Zenas BioPharma Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032 and Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2622966968","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622966968?lang=en_us&edition=fundamental","pubTime":"2026-03-27 04:01","pubTimestamp":1774555260,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., March  26, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to b","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/26/3263386/0/en/Zenas-BioPharma-Announces-Proposed-Concurrent-Public-Offerings-of-Convertible-Senior-Notes-Due-2032-and-Common-Stock.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621587507","title":"Zenas BioPharma Advances Phase 3 Orelabrutinib Trial in Progressive Multiple Sclerosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2621587507","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621587507?lang=en_us&edition=fundamental","pubTime":"2026-03-21 00:31","pubTimestamp":1774024295,"startTime":"0","endTime":"0","summary":"Zenas BioPharma, Inc. ($ZBIO) announced an update on their ongoing clinical study. Zenas BioPharma (ZBIO) is running a phase 3 trial called “A Phas...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/zenas-biopharma-advances-phase-3-orelabrutinib-trial-in-progressive-multiple-sclerosis?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/zenas-biopharma-advances-phase-3-orelabrutinib-trial-in-progressive-multiple-sclerosis?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BFSS8Q28.SGD","IE0004445239.USD","LU0354030438.USD","LU2108987350.USD","ZBIO","LU0070302665.USD","LU0170899867.USD","LU0354030511.USD","LU1069347547.HKD","IE0004445015.USD","LU2355687059.USD","LU0208291251.USD","SG9999011175.SGD","LU0320765489.SGD","LU1481011671.HKD","IE00BN29S564.USD","LU0138981039.USD","LU0731783394.SGD","BK4139","IE00BKVL7J92.USD","LU1035773651.USD","LU1481011911.USD","LU1509826696.USD","LU2087625088.SGD","SG9999003800.SGD","BK4533","SGXZ23171101.USD","LU1718418525.SGD","IE00BZ1G4Q59.USD","BK4588","LU0289960550.SGD","SG9999004303.SGD","LU1983260115.SGD","LU0742537680.HKD","LU0353189680.USD","IE00BJJMRX11.SGD","IE00B7KXQ091.USD","LU1599440770.SGD","LU1430594728.SGD","IE0005OL40V9.USD","LU0731783048.USD","IE00B4JS1V06.HKD","BK4107","LU0772969993.USD","LU1366192091.USD","PGR","IE00B775H168.HKD","IE00BJJMRY28.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620420549","title":"Wedbush Sticks to Its Buy Rating for Zenas BioPharma, Inc. (ZBIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620420549","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620420549?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:15","pubTimestamp":1773753347,"startTime":"0","endTime":"0","summary":"In a report released today, David Nierengarten from Wedbush maintained a Buy rating on Zenas BioPharma, Inc., with a price target of $45.00. Nieren...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-sticks-to-its-buy-rating-for-zenas-biopharma-inc-zbio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-sticks-to-its-buy-rating-for-zenas-biopharma-inc-zbio-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620424332","title":"Zenas BioPharma Is Maintained at Equal-Weight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2620424332","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620424332?lang=en_us&edition=fundamental","pubTime":"2026-03-17 20:07","pubTimestamp":1773749220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZBIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 17, 2026 08:07 ET (12:07 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620491426","title":"Zenas BioPharma Price Target Maintained With a $44.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2620491426","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620491426?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:04","pubTimestamp":1773745440,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZBIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 17, 2026 07:04 ET (11:04 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620342341","title":"Zenas BioPharma: De‑Risked Autoimmune Late‑Stage Assets and Strong Balance Sheet Underpin Buy Rating and $44 Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2620342341","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620342341?lang=en_us&edition=fundamental","pubTime":"2026-03-17 18:15","pubTimestamp":1773742535,"startTime":"0","endTime":"0","summary":"In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Zenas BioPharma, Inc., with a price target of $44.00. ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/zenas-biopharma-de‑risked-autoimmune-late‑stage-assets-and-strong-balance-sheet-underpin-buy-rating-and-44-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/zenas-biopharma-de‑risked-autoimmune-late‑stage-assets-and-strong-balance-sheet-underpin-buy-rating-and-44-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO","SSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620842871","title":"Zenas BioPharma price target lowered to $41 from $43 at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2620842871","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620842871?lang=en_us&edition=fundamental","pubTime":"2026-03-17 17:55","pubTimestamp":1773741354,"startTime":"0","endTime":"0","summary":"Citi lowered the firm’s price target on Zenas BioPharma (ZBIO) to $41 from $43 and keeps a Buy rating on the shares. The firm updated the company’s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-price-target-lowered-to-41-from-43-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zenas-biopharma-price-target-lowered-to-41-from-43-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620432534","title":"IPO-Related Securities Class Action Poses Ongoing Financial and Operational Risks for Zenas BioPharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2620432534","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620432534?lang=en_us&edition=fundamental","pubTime":"2026-03-17 14:00","pubTimestamp":1773727227,"startTime":"0","endTime":"0","summary":"Zenas BioPharma, Inc. (ZBIO) has disclosed a new risk, in the Litigation & Legal Liabilities category. Securities class action litigation represent...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ipo-related-securities-class-action-poses-ongoing-financial-and-operational-risks-for-zenas-biopharma?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ipo-related-securities-class-action-poses-ongoing-financial-and-operational-risks-for-zenas-biopharma?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620497345","title":"Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620497345","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620497345?lang=en_us&edition=fundamental","pubTime":"2026-03-17 06:01","pubTimestamp":1773698504,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA43MCV2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620497659","title":"Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620497659","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620497659?lang=en_us&edition=fundamental","pubTime":"2026-03-17 06:01","pubTimestamp":1773698460,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., March  16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/16/3256797/0/en/Zenas-BioPharma-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619468256","title":"Zenas BioPharma Inc. Announces Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2619468256","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619468256?lang=en_us&edition=fundamental","pubTime":"2026-03-16 20:27","pubTimestamp":1773664022,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 16, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL87tDtc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619163457","title":"Earnings Flash (ZBIO) Zenas BioPharma Posts Q4 Net Loss $4.54 a Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2619163457","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619163457?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:23","pubTimestamp":1773660236,"startTime":"0","endTime":"0","summary":"Earnings Flash (ZBIO) Zenas BioPharma Posts Q4 Net Loss $4.54 a Share","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619457153","title":"Zenas BioPharma Q4 EPS $(4.54) Down From $(1.26) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2619457153","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619457153?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:22","pubTimestamp":1773660136,"startTime":"0","endTime":"0","summary":"Zenas BioPharma (NASDAQ:ZBIO) reported quarterly losses of $(4.54) per share. This is a 260.32 percent decrease over losses of $(1.26) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51264898/zenas-biopharma-q4-eps-4-54-down-from-1-26-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619452190","title":"Zenas BioPharma Q4 net loss rose 357% to USD 240.44 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2619452190","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619452190?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:01","pubTimestamp":1773658919,"startTime":"0","endTime":"0","summary":"Zenas published a fourth-quarter and full-year 2025 earnings press release. For FY 2025, Zenas reported total revenue of USD 10 million and a net loss of USD 377.74 million. In Q4 2025, R&D expense rose 13.22% to USD 55.72 million, driven by higher personnel costs and increased orelabrutinib clinical and regulatory costs, partly offset by lower obexelimab clinical and manufacturing costs. Q4 2025 net loss was USD 240.44 million, and acquired in-process R&D expense was USD 166.67 million related to the InnoCare licensing deal for orelabrutinib, ZB021 and ZB022. Zenas ended 2025 with cash, cash equivalents and investments of USD 360.46 million and said it expects to submit an obexelimab BLA for IgG4-RD to the FDA in Q2 2026 and report topline Phase 2 SunStone results in SLE in Q4 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for info","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL9zyh50:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619529024","title":"Press Release: Zenas BioPharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2619529024","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619529024?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:01","pubTimestamp":1773658860,"startTime":"0","endTime":"0","summary":"- Obexelimab marketing applications for the treatment of IgG4-RD expected to be submitted to the FDA in Q2 2026 and the EMA in H2 2026 based on the Phase 3 INDIGO trial results -. - Topline results of the global Phase 2 SunStone trial of obexelimab in SLE expected in Q4 2026 -. - New, half-life extended anti-CD-19 and Fc<GAMMA>RIIb mAb  progressing toward clinical development -. - Global orelabrutinib Phase 3 trial for primary progressive multiple sclerosis  ongoing; global Phase 3 trial for non-active secondary progressive MS expected to be initiated in Q1 2026 -. - Oral, IL-17AA/AF inhibitor  Phase 1 trial expected to be initiated in 2Q 2026 with initial clinical data by year-end -. obexelimab for the treatment of Immunoglobulin G4-Related Disease","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225283273.USD","LU1791710582.SGD","LU2111349929.HKD","LU2357305700.SGD","LU0912757837.SGD","LU1244550494.USD","LU0320765646.SGD","LU0314104364.USD","IND","SLE","LU1244550221.USD","BK4516","LU2089283258.USD","LU1074936037.SGD","LU1732799900.SGD","LU1363072403.SGD","LU2347655156.SGD","LU0267386448.USD","LU0971096721.USD","LU2089284900.SGD","LU1791710400.SGD","LU1668664300.SGD","MAA","LU0006306889.USD","SOFR","LU0528227936.USD","LU1720051108.HKD","ZBIO","LU1548497426.USD","LU1989772840.SGD","LU2133065610.SGD","BK4581","IE00BZ1G4Q59.USD","BK4534","LU1989772923.USD","LU1720051017.SGD","LU2023251221.USD","LU1732800096.USD","BK4588","LU0158827948.USD","LU0882574139.USD","BK4504","LU0234570918.USD","LU0557290698.USD","LU0106261372.USD","BK4585","BK4139","LU0098860793.USD","LU0795875169.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":6,"totalSize":118,"code":"91000000","status":"200"}]}}